EX-10.9



 Exhibit 10.9 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN
FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

 
  
 



 
 August 1, 2014 
 Daniel
A. de Boer 
 Chief Executive Officer 
 ProQR Therapeutics B.V.

 Darwinweg 24, 2333CR Leiden, 
 The Netherlands 

 

			
	Development Program:	  	Clinical Trials for QR-010
	Amount of Award:	  	$3 million [***]
	Name of Awardee:	  	ProQR Therapeutics (“PROQR”)

 Dear Mr. de Boer: 

We are pleased to inform you that the Cystic Fibrosis Foundation Therapeutics, Inc. (“CFFT”) is hereby issuing an award for the
Development Program described in Exhibit A and disbursed in accordance with Exhibit B up to the amount indicated above. The Award is intended to foster CFFT’s charitable purpose to discover therapies for the cure of
cystic fibrosis. The awardee, PROQR, shall be responsible for the payment of all of the remaining costs required to complete the Development Program and for costs associated with continuing CRE necessary to further develop and commercialize the
product. Each party’s obligations hereunder will commence and apply upon the execution of this Agreement. The Award is subject to the following terms, conditions and policies of this Letter Agreement (“Agreement”): 

1. Disbursement of Award; CFFT Know-How; Reports. 

(a) The Award will be disbursed by CFFT to PROQR in accordance with the Milestone Payment Schedule set forth in Exhibit B. Any
CFFT funds not expended on the Development Program must be returned to CFFT, and upon such return, the amounts of such returned funds will not be included as part of the “Award” for purposes of calculating any royalties or other amounts
owed by PROQR to CFFT pursuant to Paragraph 2(d). 
 (b) To the extent CFFT provides or makes available any information, expertise,
know-how or other intellectual property related to cystic fibrosis or the treatment, prevention, or cure thereof (“CFFT Know-How”) to PROQR, CFFT hereby grants to PROQR a non-exclusive, transferable, sublicensable (through multiple tiers),
worldwide right and license under all of CFFT’s rights in such CFFT Know-How to assist PROQR to research, develop, commercialize, make, have made, use, sell, have sold, offer for sale, import, export and otherwise exploit the Product. 

(c) PROQR agrees to provide CFFT and the Project Advisory Group (“PAG”) specified below with a reasonably detailed, written report
every three (3) months, summarizing progress toward achieving the goals of the Development Program. In addition, PROQR shall prepare and deliver to CFFT a closing report within thirty (30) days after the completion of the Development
Program. 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS
EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 







 2. Royalties. In consideration of CFFT’s Award under this Agreement, PROQR agrees to pay to CFFT
royalties as follows: 
 (a) PROQR shall pay a one-time royalty to CFFT in an amount equal to five (5) times the Royalty Cap. Such
amount shall be paid in three (3) equal installments: the first within ninety (90) days of the first commercial sale of the Product; and the remaining installments on or before the first and second anniversaries of such date. 

(b) In addition to the royalty payable pursuant to subparagraph (a) above, PROQR shall pay to CFFT a one-time royalty equal to the Actual
Award within sixty (60) days after the end of the first calendar year after which aggregate Net Sales of the Product exceed $500 million. 

(c) In the event of a license, sale or other transfer of the Product (excluding Net Sales or sales of the Product between or among PROQR and
its Affiliates and sublicensees for resale, or for use in the production or manufacture of the Product or any sale or other distribution for use in a clinical trial or other Development activity, for compassionate or named-patient use or for test
marketing) or a Change of Control transaction, PROQR shall pay to CFFT two (2) times the amount of the Actual Award plus the Prior Award. Such payment shall be made within sixty (60) days after any transactions giving rise to such payment.

 3. Commercially Reasonable Efforts. PROQR shall use Commercially Reasonable Efforts to conduct the Development Program during the term of this
Agreement. After the Development Program is completed, PROQR shall exercise Commercially Reasonable Efforts to develop the Product and shall continue to report to CFFT annually on the progress of its development activities regarding the Product
until the earlier of first commercial sale of the Product or such research efforts are abandoned by PROQR, its Affiliates and its sublicensees, solely as a result of scientific failure. 

4. Program Advisory Group (“PAG”). 

(a) PROQR and CFFT shall form a PAG to oversee the Development Program. The PAG shall consist of two (2) individuals appointed by PROQR
and two (2) individuals appointed by CFFT. One of such individuals from PROQR and CFFT, respectively, shall be the principal liaison to the Development Program. A party may replace the individuals appointed by such party and designate a
different individual as the principal liaison upon written notice to the other party. 
 (b) The role of the PAG shall be to determine,
discuss and propose amendments to the Development Program and budget, to determine whether payment milestones have been achieved, and to consider other issues raised by either party relating to the Development Program, provided that no change to the
Development Program shall be made without the written agreement of both parties. The PAG shall terminate and cease to exist on the earlier of the commercialization of the Product or the termination of this Agreement. CFFT will participate in the PAG
as part of its oversight responsibilities, in order to protect CFFT. 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND
REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE
SECURITIES EXCHANGE ACT OF 1934. 

  
 2 








 5. Interruption License. Upon written notice from CFFT following an Interruption (the “Interruption
Notice”), PROQR shall elect, within thirty (30) days of such Interruption Notice, one of the following options by notice to CFFT: 

(a) PROQR shall reasonably demonstrate, in the form of a written progress report, that an Interruption has not occurred, or that PROQR, an
Affiliate thereof, or a licensee or sublicensee of either of the foregoing is exercising Commercially Reasonable Efforts to research, develop or commercialize the Product; 

(b) PROQR shall provide CFFT with notice within such thirty (30) day period that PROQR, an Affiliate thereof, or a licensee or
sublicensee of either of the foregoing, has plans to resume Commercially Reasonable Efforts to develop or commercialize the Product and resumes such Commercially Reasonable Efforts within the ninety (90) day period following such notice; 

(c) PROQR shall grant CFFT an Interruption License, as set forth below; or 

(d) PROQR may elect within thirty (30) days of the Interruption Notice to pay to CFFT the greater of (A) two (2) times the
Actual Award, and (B) the total of the Actual Award and the Prior Award plus Interest up to the time of such election; and in the event of such election and payment, this Paragraph 5 shall no longer be applicable and ProQR shall have no
further obligations to CFFT under this Paragraph 5. 
 If PROQR has elected (a) or (b) above within thirty (30) days of
the Interruption Notice, the Interruption Notice shall be deemed satisfied and be of no further force or effect unless CFFT notifies PROQR within thirty (30) days after receipt of PROQR’s progress report under (a) above or provides
notice under (b) above that CFFT disputes such progress report or notice, as the case may be. If CFFT provides timely notice of its dispute, the parties shall resolve such dispute in accordance with the dispute resolution provision of this
Agreement. 
 If PROQR has elected (a) or (b) above, CFFT has disputed such election, the resolution of the dispute is concluded
and the final outcome of such dispute resolution is that such election was defective, PROQR shall be deemed to have made the election specified in (c) above. If PROQR has made (or is deemed to have made) the election specified in
(c) above, PROQR hereby grants to CFFT an Interruption License effective upon such election (or deemed election) (such date, the “Interruption License Effective Date”). The Interruption License shall be an exclusive (even as to
PROQR), worldwide license to CFFT under the PROQR Development Program Technology to manufacture, have manufactured, license, use, sell, offer to sell, and support the Product in the Field. PROQR shall deliver to CFFT, within ninety (90) days
after the Interruption License Effective Date, a copy of all materials and data in its possession or control generated in the performance of the Development Program and PROQR Development Program Technology, to the extent required by CFFT to make,
use, or sell the Product in the Field. In the event that PROQR assigns all of or certain of its rights and obligations to develop and commercialize the Product at any time to a third party, such third party shall be subject to the obligations of the
Interruption License. The Interruption License shall be deemed to constitute intellectual property as defined in Section 364(n) of the U.S. Bankruptcy Code,; provided, however, that nothing in this Agreement shall be deemed to constitute a
present exercise of such rights and elections. 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH
“[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT
OF 1934. 

  
 3 








 6. Indemnification by PROQR. 

(a) PROQR shall indemnify, defend and hold harmless CFFT, its Affixes, and their respective directors, officers, employees, consultants,
committee members, volunteers, agents and representatives and their respective successors, heirs and assigns (each, an “CFFT Indemnitee”), from and against any and all claims, suits and demands of third parties and losses, liabilities,
damages for personal injury, property damage or otherwise, costs, penalties, fines and expenses (including court costs and the reasonable fees of attorneys and other professionals) payable to such third parties arising out of, and relating to any
such third party claims resulting from: 
 (i) the conduct of the Development Program by PROQR or its Affiliates or their respective
directors, officers, employees, consultants, agents, representatives, licensees, sublicensees, subcontractors and/or investigators (each, a “PROQR Party”) under this Agreement and/or pursuant to one or more agreements between PROQR and any
PROQR Party, or any actual or alleged violation of law resulting therefrom; 
 (ii) PROQR’s or its Affiliates’ development,
manufacture, or commercialization of the Product developed in whole or in part as a result of the Development Program; 
 (iii) any claim of
infringement or misappropriation with respect to the conduct of the Development Program by or on behalf of PROQR or PROQR’s or its Affiliates’ third party licensees’ or sublicensees’ (for the avoidance of doubt, third party
licensee or sublicensee shall exclude CFFT or a CFFT licensee or sublicensee) manufacture, use, sale, or import of the Product developed in whole or in part as a result of the Development Program; and 

(iv) any tort claims of personal injury (including death) relating to or arising out of any such injury sustained as the result of, or in
connection with, the conduct of the Development Program by or on behalf of PROQR or PROQR’s, its Affiliates’, or PROQR’s or its Affiliates’ third party licensees’ or sublicensees’ (other than CFFT or any of CFFT’s
licensees’ or sublicensees’) development, manufacture, or commercialization of the Product developed in whole or in part as a result of the Development Program; in each case except to the extent the claim, suit, demand, liability, damage,
or loss results from the negligence, willful misconduct or other fault of a CFFT Indemnitee. 
 (b) CFFT will indemnify, defend and hold
harmless PROQR, its Affiliates and their respective directors, officers, employees, consultants, agents and representatives and their respective successors, heirs and assigns (“PROQR Indemnitees”) from and against any and all claims, suits
and demands of third parties and losses, liabilities, damages for personal injury, property damage or otherwise, costs, penalties, fines and expenses (including court costs and the reasonable fees of attorneys and other professionals) payable to
such third parties arising out of, resulting from, or relating to any exercise of any rights under the Interruption License by or on behalf of CFFT, any designee, assignee or successor in interest thereto, or any licensee or sublicensee of any of
the foregoing, except to the extent the claim, suit, demand, liability, damage or loss results from the negligence or willful misconduct of a PROQR Indemnitee after the effective date of the Interruption License. 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN
FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

  
 4 








 (c) A party entitled to indemnification under this Paragraph 6 (the “Indemnified
Party”) will promptly notify the other Party (the “Indemnifying Party”) of any claims, suits, demands, losses, liabilities, damages costs, penalties, fines, or expenses subject to indemnification under this Paragraph 6 of which
it is made aware. The Indemnified Party will cooperate, and exert efforts to cause other Indemnified Parties to cooperate, in assisting the Indemnifying Party in presenting a defense, if requested to do so. The Indemnifying Party shall have sole
control to select defense counsel, direct the defense of any such complaint or claim, and the right to settle claims at the Indemnifying Party’s sole expense, provided that any such settlement does not incur non-indemnified liability for or
admit fault by any Indemnified Party. In the event a claim or action is or may be asserted, the Indemnified Party shall have the right to select and to obtain representation by separate legal counsel. If the Indemnified Party exercises such right,
all costs and expenses incurred for such separate counsel shall be borne by the Indemnified Party. No Indemnified Party shall settle or enter into any voluntary disposition of any matter subject to indemnification under this Paragraph 6 without
the prior written consent of the Indemnifying Party, such consent not to be unreasonably withheld. 
 7. Insurance. PROQR shall maintain at its own
expense, with a reputable insurance carrier, coverage for PROQR, its Affiliates, and their respective employees written on a per a per occurrence basis commensurate with a reasonable assessment of the risks associated with the development efforts
being conducted by PROQR, the following policies: Commercial general liability insurance, including contractual liability as respects this Agreement for bodily injury and property damage and, no later than the first use administration of the Product
to a human subject, the Product liability and clinical trials liability. 
 Maintenance of such insurance coverage will not relieve PROQR of
any responsibility under this Agreement for damage in excess of insurance limits or otherwise. On or prior to the Effective Date of this Agreement, PROQR shall provide CFFT with an insurance certificate from the insurer(s), broker(s) or agent(s)
(hereinafter collectively the “Insurance Providers”) evidencing the applicable insurance coverage. At its request, CFFT may review PROQR’s insurance coverage with relevant PROQR personnel no more than one time per year. 

8. Intellectual Property Rights. All inventions, data, know-how, information, results, analyses, and other intellectual property rights resulting from
the Development Program shall, as between the parties, be owned by PROQR and the preparation, filing and maintenance of all patents resulting from the Development Program shall, as between the parties, be the sole responsibility, and unfertile sole
control, of PROQR. Subject to Paragraph 5, CFFT hereby assigns and transfers to PROQR all of CFFT’s right, title, and interest in and to all inventions and other intellectual property resulting from the Development Program, CFFT’s access
to, or knowledge or use of, any PROQR Development Program Technology, the Product, or confidential or proprietary information of PROQR, and all intellectual property rights related to any of the foregoing, free and clear of all liens, claims, and
encumbrances. 
 9. Termination of Agreement. 

(a) Either party may terminate this Agreement for cause, without prejudice to any other remedies available to the terminated party with
respect thereto, by providing the other party with written notice of such cause and intent to terminate; provided, however, that the other party 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN
FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

  
 5 








 
shall have thirty (30 days following the receipt of written notice to cure such cause. For this Paragraph 9, “cause” shall mean (i) a party’s material breach of its
covenants or obligations under this Agreement, (ii) a bankruptcy or similar filing by a party or a proceeding under the applicable bankruptcy laws or under any dissolution or liquidation law or statute now or hereafter in effect and filed
against such party or all or substantially all of its assets if such filing is not dismissed within sixty (6) days after the date of its filing, or (iii) PROQR’s material failure to achieve any Milestone within ninety (90) days
of its anticipated achievement day. 
 (b) The following provisions shall survive the termination of this Agreement: Paragraphs 2, 6,
8, 9, 10 (solely with the respect to the confidentiality obligations therein), 11, and 12. In addition, the following provision also shall survive in the event of termination of this Agreement by CFFT pursuant to subparagraph (a) above:
Paragraph 5 (to the extent the Interruption License has been granted and solely for purposes thereof). 
 10. Audits. At the request of CFFT,
from time to time, PROQR shall permit CFFT, upon reasonable notice, to audit and examine such books and records of PROQR as may be necessary for verifying PROQR’s expenditures of the Award and the payment of royalties, if any, but no more
frequently than once every calendar year. All non-public information made available by PROQR as part of any such audit, as part of any other reports (whether written or non-written), or otherwise under this Agreement (including, but not limited to,
in connection with the PAG) shall be regarded as PROQR’s confidential information and CFFT hereby covenants that, except to the extent required by law (provided that CFFT promptly notifies PROQR of such requirement and permits PROQR to seek,
and reasonably cooperates with PROQR at PROQR’s expense in seeking, a protective order therefor or other confidential treatment thereof), it shall not use any such information for any purpose other than determining whether PROQR has complied
with its obligations hereunder (provided that CFFT may also use information provided through the PAG to further the purposes of the PAG hereunder) or, in the event of the grant of the Interruption License, the exercise thereof, or disclose any such
information to any third party, and shall maintain such information in confidence in a manner at least as restrictive as its manner of treating its own confidential information of similar nature and in any event not less than with a reasonable
degree of care. 
 11. Miscellaneous. 

(a) Governing Law. this Agreement shall be governed by and construed in accordance with the internal laws of the State of Maryland. 

(b) Dispute Resolution. 
 (i) In
the event of any dispute, claim or controversy arising out of, relating to or in any way connected to the interpretation of any provision of this Agreement, the performance of either party under this Agreement or any other matter under this
Agreement, including any action in tort, contract or otherwise, at equity or law (a “Dispute”), either party may at any time provide the other party written notice specifying the terms of such Dispute in reasonable detail. As soon as
practicable after receipt of such notice, an officer of each party shall meet at a mutually agreed upon time and location to engage in good faith discussions for the purpose of resolving such Dispute. If the Dispute is not resolved within
thirty (3) days of such notice, either party may institute arbitration in accordance with (ii) below. 
 CERTAIN CONFIDENTIAL
PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL
TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

  
 6 








 (ii) In the event any Dispute is not resolved in accordance with (i) above, such Dispute
shall be resolved by final and binding arbitration. Whenever a party decides to institute arbitration proceedings, it shall five written notice to that effect to the other party. Arbitration shall be held in Washington, D.C., according to the
then-current commercial arbitration rules of the Center for Public Resources (“CPR”), except to the extent such rules are inconsistent with this subparagraph. The arbitration will be conducted by one (1) independent, neutral
arbitrator who shall be mutually acceptable to both parties, such acceptance not to be unreasonably withheld, and who shall be appointed in accordance with CPR rules. If the parties are unable to mutually agree on such an arbitrator, then the
arbitrator shall be appointed in accordance with CPR rules. Any arbitrator chosen hereunder shall have educational training and industry experience sufficient to demonstrate a reasonable level of relevant scientific, financial, medical and industry
knowledge. Within twenty (20) days of the selection of the arbitrator, each party shall submit to the arbitrator a proposed resolution of the Dispute that is the subject of the arbitration (the “Proposals”). The arbitrator shall
thereafter select one of the Proposals so submitted as the resolution of the Dispute, but may not alter the terms of either Proposal and may not resolve the Dispute in a manner other than by selection of one of the submitted Proposals. If a party
fails to submit a Proposal, the arbitrator shall select the Proposal of the other party as the resolution of the Dispute. The arbitrator shall agree to render its opinion within thirty (30) days of the final arbitration hearing. No arbitrator
shall have the power to award punitive damages regardless of whether any such damages are contained in a Proposal, and such award is expressly prohibited. The proceedings and decisions of the arbitrator shall be confidential, final and binding on
all of the parties. Judgment on the award so rendered may be entered in any court having jurisdiction thereof. The parties shall share the costs of arbitration according to the decision of the arbitrator. Nothing in this subparagraph will preclude
either party from seeking equitable or injunctive relief, or interim or provisional relief, from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction, or any other form of permanent or interim equitable
or injunctive relief, concerning a dispute either prior to or during any arbitration. 
 (c) This Agreement may be executed in two (2)
or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same Agreement. Facsimile and other electronically scanned signatures shall have the same effect as their originals. 

(d) All communications between the parties with respect to any of the provisions of this Agreement will be sent to the addresses set out
below, or to such other addresses as may be designated by one party to the other by notice pursuant hereto, by prepaid, certified air mail (which shall be deemed received by the other party on the seventh (7th) business day following deposit in the mail), or other electronic means of communication excluding facsimile transmission (each of which shall be deemed received when transmitted), with
confirmation by first class letter, postage pre-paid, given by the close of business on or before the next following business day: 
 if to
CFFT, at: 
 Robert J. Beall, Ph.D 

6931 Arlington Rd., Suite 200 

Suite 200 
 Bethesda, Maryland
20814 
 Phone: 301-907-2541 

Fax: 301-907-2699 
 Email: 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN
FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

  
 7 








 with a copy to: 

Schaner & Lubitz, PLLC 

6931 Arlington Rd., Suite 200 

Bethesda, Maryland 20814 
 Attn:
Kenneth I. Schaner, Esq. 
 Phone: 240-482-2848 

Fax: 202-470-2241 
 E-mail: 

if to PROQR, at: 
 ProQR
Therapeutics B.V. 
 Darwinweg 24, 2333 CR Leiden 

The Netherlands 
 Attn: Daniel A.
de Boer (CEO) 

			
	Phone:	 	+31 85 4 89 49 32
	E-mail:	 	

 With a copy to: 

ProQR Therapeutics B.V. 

Darwinweg 24, 2333 CR Leiden 
 The
Netherlands 
 Attn: Rene K. Beukema (General Counsel) 

			
	Phone:	 	+ 31 85 4 89 49 32
	E-mail:	 	

 (e) The paragraph headings are for convenience only and will not be deemed to affect in any way the language
of the provisions to which they refer. 
 (f) PROQR will not, by amendment of its organizational or governing documents, or through
reorganization, recapitalization, consolidation, merger, dissolution, sale, transfer or assignment of assets, issuance of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms,
provisions, covenants or agreements of this Agreement. 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH
“[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT
OF 1934. 

  
 8 








 (g) This Agreement may not be assigned by any party without the consent of the other party,
except that either Party may assign this Agreement without such consent to an Affiliate of such party or in connection with the transfer, whether by sale of assets, merger or otherwise, of all or substantially all of the assets or business of such
party to which this Agreement relates. Any assignment that is not in accordance with this subparagraph 10(g) will be null and void ab initio. 

(h) The award is intended to constitute gross income to PROQR for United States Federal Income Tax purposes. Nothing herein contained shall be
deemed to create an agency, joint venture, amalgamation, partnership or similar relationship between CFFT and PROQR. Notwithstanding any of the provisions of this Agreement, neither party to this Agreement shall at any time enter into, incur, or
hold itself out to third parties as having authority to enter into or incur, on behalf of the other party, any commitment, expense, or liability whatsoever, and all contracts, expenses and liabilities in connection with or relating to the
obligations of each party under this Agreement shall be made, paid, and undertaken exclusively by such party on its own behalf and not as an agent or representative of the other. 

(i) The Public Affairs Department of CFFT and PROQR shall agree on any press release or other public announcement, other than an academic,
scholarly, or scientific publication, concerning the terms of this Agreement or this Award prior to its public release, except to the extent any such release or announcement is required by law, rule, or regulation or the rules of any secures
exchange. The parties agree that they intend to advance the body of general scientific knowledge of cystic fibrosis and its potential therapies and cures and the parties acknowledge that PROQR intends to, as commercially and scientifically
reasonable based on the results of the Development Program, publish the results of the Development Program in a scientific peer-reviewed publication on a timely basis. CFFT’s support for the Development Program shall be acknowledged in any
press releases and publications relating to the Development Program. 
 (j) In accordance with the U.S. Department of the Treasury
Anti-Terrorist Financing Guidelines, PROQR shall take reasonable steps to ensure that the payments received from CFFT are not distributed to terrorists or their support networks or used for activities that support terrorism or terrorist
organizations. PROQR certifies that it is in compliance with all laws, statutes and regulations restricting U.S. persons from dealing with any individuals, entities, or groups subject to Office of Foreign Assets Control (OFAC) sanctions. CFFT
reserves the right to correct any misuse of resources that are in violation of the Anti-Terrorist Financing Guidelines and may terminate this agreement immediately if a misuse occurs. PROQR shall provide copies of any public filings or releases,
including the most recent official registry documents, annual reports, and annual filings with the pertinent government, as applicable. 
 12.
Definitions. 
 (a) Unless otherwise defined in this letter, the following shall apply: 

 

	 	•	 	“Actual Award” means the total amount of the Award actually paid to PROQR. 

 CERTAIN
CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING
CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

  
 9 









	 	•	 	“Affiliate” shall mean, with respect to a party, any entity, which directly or indirectly controls, is controlled by, or is under common control with, such party. For these purposes, “control” shall
refer to (a) the ownership, directly or indirectly, of at least fifty percent (50%) of the voting securities or other ownership interest of an entity; or (b) the possession, directly or indirectly, of the power to direct the
management or policies of an entity, whether through the ownership of voting securities, by contract or otherwise. 

  

	 	•	 	“Change of Control Transaction” shall mean the consummation of a transaction, whether in a single transaction or in a series of related and substantially contemporaneous transactions, constituting (i) a
merger, share exchange or other reorganization, (ii) the sale by one or more stockholders of a majority of the voting power of PROQR, or (iii) a sale of all or substantially all of the assets of PROQR (or that portion of its assets related
to the subject matter of this Agreement), in which the stockholders of PROQR immediately prior to such transaction do not own a majority of the voting power of the acquiring, surviving or successor entity, as the case may be; provided that a Change
of Control shall not include a bona fide financing transaction for the benefit of PROQR (i.e. in which PROQR raises capital for general working or business purposes) in which voting control of PROQR transfers to one or more persons or entities who
acquire shares of PROQR, and the existing PROQR shareholders receive no consideration directly or indirectly in connection with the transaction. 

  

	 	•	 	“Commercially Reasonable Efforts” or “CRE” shall mean the level of effort, expertise and resources that is substantially and materially consistent with industry standards for companies of similar
size and financial resources to research, develop and commercialize the Product, provided such research, development and commercialization is technically feasible, devoting the degree of attention and diligence to such efforts that is substantially
and materially consistent with industry standards for a product at a comparable stage in development, with similar market potential, and taking into account, without limitation, issues of safety and efficacy, proprietary position, and competitive
environment, the regulatory environment, and other relevant scientific, technical and commercial factors, and for companies of similar size and financial resources. 


 

	 	•	 	“Field” shall mean the treatment of cystic fibrosis and other diseases caused by F508del mutation in CFTR. 

  

	 	•	 	“Interest” shall mean the prime rate applicable during the relevant time period, as published in the Wall Street Journal, plus five (5) percentage points. 


 

	 	•	 	“Interruption” shall mean the cessation of Commercially Reasonable Efforts to develop a Product for more than three hundred sixty (360) days at any time before the first commercial sale of the Product.
For clarity, delays resulting from events outside of PROQR’s reasonable control (e.g., technical difficulties, shortages of supplies or materials, delays in preclinical or clinical studies or regulatory processes, difficulties in obtaining
financing, etc.) will not be deemed cessation of Commercially Reasonable Efforts. 

  

	 	•	 	“Net Sales” shall mean, for any period, the gross amount received for sales of the Product in the Field by PROQR or any PROQR Affiliate, sublicensee or transferee as applicable (a “Selling Person”),
to a non-Affiliate of the Selling Person, less the following deductions, in each case to the extent specifically related to the Product and taken by the Selling Person or otherwise paid for or accrued by the Selling Person (“Permitted
Deductions”): 

 trade, cash, promotional and quantity discounts and inventory management fees paid to wholesalers; 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN
FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

  
 10 








 tariffs, duties, excises and taxes on sales (including sales or use taxes or value added taxes)
to the extent imposed upon and paid directly with respect to such sales (and excluding national, sales or local taxes based on income); 

freight, insurance, packing costs and other transportation charges allocated to the sale; 

invoiced amounts that are written off as uncollectible in accordance with Selling Person’s accounting policies, consistently applied; 

amounts repaid or credits taken by reason damaged goods, rejections, defects, expired dating, recalls or returns or because of retroactive
price reductions, billing errors, or trial prescriptions; 
 charge back payments, rebates and discounts granted to (i) managed
healthcare organizations, (ii) federal, state or provincial or local governments or other agencies, (iii) purchasers and reimbursers or (iv) trade customers, including wholesalers and chain and pharmacy buying groups; 

discounts paid under state legislated or seller-sponsored discount prescription drug programs or reductions for coupon and voucher programs;
and 
 document custom duties actually paid by the Selling Person. 

Sales of the Product between or among PROQR and its Affiliates and sublicensees for resale, or for use in the production or manufacture of the Product, shall
not be included within Net Sales; provided, however, that any subsequent sale of the Product (or any Product produced or manufactured using the Product) by PROQR or its Affiliate or sublicensee or transferee to another non-Affiliate third party
shall be included within Net Sales. Net Sales shall exclude any sale or other distribution for use in a clinical trial or other Development activity, for compassionate or named-patient use or for test marketing. 

 

	 	•	 	“Prior Award” shall mean $184,935, which was awarded by CFFT to PROQR pursuant to the award of December 22, 2012. 

  

	 	•	 	“Product” shall mean QR-010. 

  

	 	•	 	“PROQR Development Program Technology” shall mean all Technology discovered or developed, or controlled, by PROQR or its Affiliates, as a result of the Development Program under this Agreement (solely for
purposes of the Interruption License), including, without limitation, Technology owned or controlled by PROQR prior to PROQR’s performance of the Development Program under this Agreement that is necessary in the 


CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN
FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

  
 11 









	 	 
performance of the Development Program under this Agreement. Without limitation, PROQR Development Program Technology shall include data, technical information, source codes, know-how, inventions
(whether or not patented), trade secrets, laboratory notebooks, and processes and methods. 


  

	 	•	 	“Royalty Cap” shall mean five (5) times the Actual Award plus the Prior Award. 


We are pleased to make the Award described in this Agreement. Please indicate your agreement to the terms set forth in this Agreement by
signing below. 
  

			
	Sincerely,
	
	Cystic Fibrosis Foundation Therapeutics, Inc.
		
	By:	 	 /s/ Preston W. Campbell, III, M.D.

		
	Name:	 	 Preston W. Campbell, III, M.D.

		
	Title:	 	 Executive Vice President, Medical Affairs

	
	Agreed:
	
	ProQR Therapeutics
		
	By:	 	 /s/ Daniel A. de Boer

		
	Name:	 	 Daniel A. de Boer

		
	Title:	 	 Chief Executive Officer


 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

  
 12 








 Exhibit A 

Development Program Plan and Budget 

[***] 
 CERTAIN CONFIDENTIAL
PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL
TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

  
 A-1 








 Exhibit B 

Payment Schedule 
 [***]

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS
BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

  
 B-1